NN9211-4083 The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes: A 26 Weeks Radomised, Insulin Capped, Placebo-Controlled, Double-Blind, Parallel Group, Multinational, Multi-Centre Trial.

Project: Research project

Project Details

StatusFinished
Effective start/end date7/8/14 → 7/8/17

Funding

  • Novo Nordisk Inc. (NN9211-4083)